Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus APIDRA SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus APIDRA SOLOSTAR.
ADMELOG SOLOSTAR vs APIDRA SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Category C
Category C
Insulin
Insulin